Primary and secondary outcomes
ulcer, NRS
SECONDARY, BPH, DISEASE, ULCER, BENIGN PROSTATIC HYPERPLASIA
At study termination, more than 33% and 15% of curcumin mouthwash and curcumin-nanocapsule-receiving subjects remained ulcer free compared with none of the placebo-treated subjects, respectively. The means (SD) of WHO and NRSscales did not significantly differ between the three groups over the weeks 1 and 2 while Both WHO and NRS scales in each of the curcumin-treated groups were significantly reduced at the study periods of week 3 compared to the placebo group (P < 0.001) (Fig. 
Patient Demographics Profile and Baseline Disease CharacteristicsN: Number; SD: Standard Deviation; y: yaer; BA: Bachelor of Art; BS: Bachelor of Science; MS: Master of Science; BPH: Benign Prostatic Hyperplasia.
Variation of the primary and secondary outcomes over time; *P-value < 0.05 considered statistically significantRepeated measurement analysis compared the reduction of WHO scale at weeks 1 to 3 relative to baseline. The results indicated a statistically significant decline in the oral or topical curcumin groups vs. the placebo group. Additional analysis showed a significant reduction in NRS in both curcumin groups compared with the placebo group except for weeks 3 vs. 2 (P-Value = 0.81) and week 1 vs. baseline (P-Value = 0.29) in the control group (Table 
 Primary and secondary outcomes over the time